Ardelyx, Inc. — Q2 2014 Form 10-Q
Reporting period: Three and six months ended June 30, 2014. Unaudited interim results. Ardelyx is a clinical-stage biopharmaceutical company developing non-systemic small-molecule therapies for gastrointestinal, cardio-renal and metabolic diseases. It had no product sales; revenue came from collaboration and licensing agreements.
Financial results and position
Amounts below are in U.S. dollars; financial statement amounts are in millions unless noted.
- Q2 revenue: $9.14 million, up 25% from $7.29 million. Licensing revenue was $6.51 million (up from $1.99 million); collaborative development revenue was $2.63 million (down from $5.30 million).
- First-half revenue: $17.69 million, up 28% from $13.85 million. Licensing revenue was $9.74 million; collaborative development revenue was $7.94 million.
- Q2 operating results: Operating income was $2.75 million versus an $0.85 million operating loss in Q2 2013; operating margin was approximately 30%, versus negative 12%. Net income was $3.75 million versus a $0.89 million net loss. Basic and diluted EPS were $0.20 and $0.18, respectively.
- First-half operating results: Operating income was $2.29 million versus an $1.26 million operating loss; operating margin was approximately 13%, versus negative 9%. Net income was $0.68 million versus a $1.36 million net loss. No net income was attributable to common stockholders for first-half 2014 under the two-class EPS calculation.
- Non-operating item: Preferred-stock warrant fair-value changes reduced first-half pretax income by $1.59 million; the warrants were net exercised and the liability reclassified to equity upon the IPO. Q2 included a $1.01 million gain from this remeasurement.
- Cash flow: First-half operating cash flow was positive $22.87 million, versus negative $8.90 million in 2013. The increase was substantially driven by deferred revenue, including the $25 million AstraZeneca payment received in May, rather than product sales. Investing cash outflow was $0.74 million; IPO financing proceeds were $61.24 million.
- Liquidity and capital: Cash and cash equivalents were $117.81 million at June 30, compared with $34.44 million at year-end 2013. Working capital was $94.8 million. Total deferred revenue was approximately $56.4 million. The company reported no outstanding debt.
Material changes and business developments
- Ardelyx completed its IPO on June 24, 2014, selling 4,928,900 shares at $14 per share and receiving $61.2 million net proceeds. All outstanding convertible preferred stock converted into common stock; preferred-stock warrants were net exercised.
- Under its AstraZeneca agreement for tenapanor, Ardelyx received a $25 million payment after the first patient was dosed in a Phase 2b hyperphosphatemia trial. Because the payment was treated as a non-substantive milestone, it was deferred and is being recognized over the estimated performance period through December 2016. The company reported up to $795 million in potential future AstraZeneca development, launch, commercialization and sales milestones, subject to achievement of contractual conditions.
- Ardelyx recognized a $1.25 million Sanofi license payment after completing technology transfer for its NaP2b inhibitor program. Sanofi is responsible for program costs and holds an option to obtain an exclusive development and commercialization license; up to $196.8 million in future milestones and tiered royalties are potential, not assured.
- Q2 R&D expense fell 28% year over year to $5.18 million, mainly because Ardelyx conducted less AstraZeneca-reimbursed tenapanor development work; discovery research expense increased. First-half R&D declined 3% to $12.82 million. G&A rose 32% in Q2 and 33% for the first half, including higher professional-services and personnel costs.
Outlook, commentary and risks
- Management said cash resources were expected to fund projected operating requirements for at least the next 12 months, while noting that operating plans and financing needs could change. The company may require additional capital or partnerships to advance programs.
- Ardelyx may elect to invest $20 million, $30 million or $40 million in the first Phase 3 tenapanor program to increase its royalty by 1%, 2% or 3%, respectively. The choice depends on clinical development and entails risk of no return if the program fails.
- Tenapanor was the company’s only product candidate in clinical trials. The filing describes a prior Phase 2a ESRD fluid-overload study that confirmed pharmacological activity but missed its primary endpoint, and delayed enrollment in an ongoing CKD Phase 2a study due to restrictive eligibility criteria.
- Key uncertainties include clinical efficacy and safety, trial timing and enrollment, regulatory approval, manufacturing, competing therapies, reimbursement and the performance or priorities of collaboration partners. Reported tenapanor-related side effects included diarrhea and other gastrointestinal symptoms and changes in electrolytes.
- Management reported effective disclosure controls as of June 30, 2014, and no material litigation. It expected higher costs from operating as a public company. The filing also notes potential Medicare ESRD drug-payment bundling beginning in 2024, which could pressure future pricing.
Important facts for investors to verify
- Progress, enrollment and results of the tenapanor trials, including the CKD study and AstraZeneca’s Phase 2b hyperphosphatemia program.
- Whether AstraZeneca continues development across indications and whether contractual milestones are achieved; verify the timing and accounting treatment of milestone revenue.
- Whether Sanofi exercises its NaP2b option and advances the program toward clinical testing.
- Cash burn and runway as unpartnered research, public-company costs and any Phase 3 co-funding decision affect spending; operating cash flow benefited from deferred collaboration receipts.
- Potential dilution and share-supply effects following the IPO, including the December 2014 lock-up expiration described in the filing.